Scientists at the Karolinska Institutet in Sweden have found a new region in the c-Myc oncogene that would allow the development of a binding compound to target it. Their discovery is based on a ...

The protein produced by the MYC oncogene is a well-known foe in the oncology world. Its presence is associated with treatment-resistant cancer cells, which grow uncontrollably and evade the immune ...

There is increasing evidence that sustained oncogene expression may be required to maintain the cancer state, implying that therapeutic strategies that use transient pharmacological inactivation may ...

WEST LAFAYETTE, Ind. — Could a natural check on cancer be used to stop the disease? It’s possible, but to leverage a system that nature designed, we must first understand it. Researchers led by a team ...

Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few side effects, is tolerable, and stabilizes disease in some patients. Developed ...